Gabriella Gobbi
Professor of Psychiatry at McGill University and Staff Psychiatrist at the MUHC Mood Disorders Program
Data updated
Research Footprint
Gabriella Gobbi appears in 5 tracked papers (2016–2022), most studied alongside LSD, Psilocybin and Ketamine, across Depressive Disorders, Interpersonal Functioning & Social Connectedness and Anxiety Disorders.
Most-cited paper: Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine (252 citations).
Frequent co-authors: Danilo De Gregorio, Katrin Preller and Boris Heifets.
Background & Research
Dr. Gabriella Gobbi is an Italian-Canadian psychiatrist and neuroscientist at McGill University. She received her MD and psychiatry specialty training in Rome, earned a PhD in neuroscience in Cagliari, and completed postdoctoral training at McGill before becoming a professor in the Department of Psychiatry. Her research spans psychopharmacology and bench-to-bedside studies of mood and anxiety disorders, including psychedelic mechanisms and therapeutic potential.
Key Impact
She is a leading translational psychiatry researcher whose lab has published influential work on LSD and other psychedelics in preclinical and clinical mental health contexts.
Collaboration Network
3 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Gabriella Gobbi is associated with.